Herspiegel Consulting, the Yardley supplier of business guidance to the life-sciences and pharmaceutical industries, has received a “growth investment” from DFW Capital Partners in Teaneck, N.J.

Founded in 2007, Herspiegel Consulting advises start-ups to Fortune 100 pharmaceutical clients on commercial projects. Its services address the details of product launch readiness, marketing, market access, medical affairs, and patient services.

The investment from DFW — for an undisclosed amount — will accelerate Herspiegel’s growth trajectory, It will seed efforts to expand geographically and in the scope and types of services it offers clients, as it continues to build on its industry-leading capabilities and reach.

“Herspiegel is rapidly accelerating its growth. And with this investment from DFW, we will be extremely well positioned to grow our offerings for our clients and expand into new geographic markets,” CEO Brent Herspiegel said.

Beth Schurman, Chief Operating Officer, Herspiegel, added, “Our clients are grappling with complex commercial strategy and execution issues in the pharmaceutical industry, and this investment will help us better serve their constantly evolving needs.”

DFW Operating Partner Kurt Brykman — who possesses deep pharmaceutical consulting experience and previously served in leadership roles with PAREXEL Consulting, Kinapse, and Medpace — will join Herspiegel Consulting’s Board of Directors.